Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.

Adrenocortical carcinoma (ACC) is a rare disease with an overall poor but heterogeneous prognosis. This heterogeneity could reflect different mechanisms of tumor development. Gene expression profiling by transcriptome analysis led to ACC being divided into two groups of tumors with very different outcomes. Somatic inactivating mutations of the tumor suppressor gene TP53 and activating mutations of the proto-oncogene β-catenin (CTNNB1) are the most frequent mutations identified in ACC. This study investigates the correlation between p53 and β-catenin alterations and the molecular classification of ACC by transcriptome analysis of 51 adult sporadic ACCs. All TP53 and CTNNB1 mutations seemed to be mutually exclusive and were observed only in the poor-outcome ACC group. Most of the abnormal p53 and β-catenin immunostaining was also found in this group. Fifty-two percent of the poor-outcome ACC group had TP53 or CTNNB1 mutations and 60% had abnormal p53 or β-catenin immunostaining. Unsupervised clustering transcriptome analysis of this poor-outcome group revealed three different subgroups, two of them being associated with p53 or β-catenin alterations, respectively. Analysis of p53 and β-catenin target gene expressions in each cluster confirmed a profound and anticipated effect on tumor biology, with distinct profiles logically associated with the respective pathway alterations. The third group had no p53 or β-catenin alteration, suggesting other unidentified molecular defects. This study shows the important respective roles of p53 and β-catenin in ACC development, delineating subgroups of ACC with different tumorigenesis and outcomes.

[1]  P. Igaz,et al.  Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed , 2010, Oncogene.

[2]  J. Bertherat,et al.  The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses , 2010, Trends in Endocrinology & Metabolism.

[3]  J. Bertherat,et al.  Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. , 2010, Human molecular genetics.

[4]  J. Bertherat,et al.  Pathogenesis of adrenocortical cancer. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[5]  Martin Fassnacht,et al.  Clinical management of adrenocortical carcinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[6]  Bertrand Dousset,et al.  Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[8]  J. Bertherat,et al.  Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. , 2008, The Journal of clinical endocrinology and metabolism.

[9]  G. Hammer,et al.  Targeted disruption of β-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex , 2008, Development.

[10]  I. Bourdeau,et al.  Frequent mutations of β‐catenin gene in sporadic secreting adrenocortical adenomas * , 2007, Clinical endocrinology.

[11]  J. Bertherat,et al.  Adrenocortical cancer: pathophysiology and clinical management. , 2007, Endocrine-related cancer.

[12]  C. Elie,et al.  Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity , 2007, Clinical Cancer Research.

[13]  J. Bertherat,et al.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.

[14]  S. Clark,et al.  Mutation and methylation analysis of TP53 in adrenal carcinogenesis. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  F. Berger,et al.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. , 2005, The Journal of clinical endocrinology and metabolism.

[16]  Paul G Gauger,et al.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.

[17]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Baudin,et al.  Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. , 2001, Cancer research.

[19]  G. Chrousos,et al.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.

[20]  P. Kleihues,et al.  p53 Mutations in sporadic adrenocortical tumors , 1993, International journal of cancer.

[21]  C. Elie,et al.  Somatic TP 53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17 p 13 Loss of Heterozygosity , 2007 .